- Companies
- Heyuan Biotechnology
Heyuan Biotechnology Valuation, Funding & Investors
Heyuan Biotechnology is valued at $3B as of June 2020.
Last Heyuan Biotechnology valuation
$3B
Series C · Jun 2020
Last Heyuan Biotechnology funding round
$300M
Series C · Jun 2020
Cumulative funding Heyuan Biotechnology raised
$300M
across 1 funding round
Key investors in Heyuan Biotechnology
Morningside
Loyal Valley Capital
Boyuan Capital
Kunlun Capital
Jinpu Investment
Sherpa Capital
About Heyuan Biotechnology
Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services
Valuation
$3B (Jun 2020)
Heyuan Biotechnology Valuation
Heyuan Biotechnology is currently valued at $3B, based on its Series C in June 2020.
The $300M round was led by Loyal Valley Capital, with participation from Kunlun Capital, Jinpu Investment, Sherpa Capital, Morningside and Boyuan Capital.
Heyuan Biotechnology valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2020 | Series C | $3B |
Heyuan Biotechnology Funding History
Heyuan Biotechnology has raised a total of $300M across 1 funding round.
Heyuan Biotechnology funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2020 | Series C | Loyal Valley Capital (lead); Kunlun Capital; Jinpu Investment; Sherpa Capital; Morningside; Boyuan Capital | $300M | $3B | Heyuan Biotechnology is a biotechnology company specializing in gene therapy services, offering gene therapy vectors, gene function research, drug targets, and efficacy evaluation for basic gene therapy research. The company completed a Series C funding round on May 31, 2020, raising $300 million led by Loyal Valley Capital, with participation from Morningside and Sherpa Capital, alongside other investors including Boyuan Capital, Jinpu Investment, and Kunlun Capital. The company operates in a competitive landscape of gene therapy and biotech CRO services, with peers like Zhishan Weixin Biotechnology focusing on gene-drug R&D for genetic diseases. |
Who has invested in Heyuan Biotechnology?
6 investors have backed Heyuan Biotechnology across its funding rounds, including Morningside, Loyal Valley Capital, Boyuan Capital, Kunlun Capital, Jinpu Investment and Sherpa Capital.
Lead investors include Loyal Valley Capital.
Heyuan Biotechnology Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Jun 2020 | ||
| 1 | Lead | Jun 2020 | ||
| 1 | Participant | Jun 2020 | ||
| 1 | Participant | Jun 2020 | ||
This data is available for Pro users. Sign up to see all 6 Heyuan Biotechnology investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialHeyuan Biotechnology Competitors
Heyuan Biotechnology competitors include listed companies like Betta Pharmaceuticals, CareDx, Veracyte and GRAIL, and private ones like ArsenalBio and Formation Bio.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1.9B | - | ||
| Private | - | - | $1B | - | ||
| Publicly listed | $538M | $155M | $2.9B | 5.5x | ||
| Publicly listed | $380M | ($10M) | $2.8B | 5.3x | ||
| Publicly listed | $517M | $77M | $3.3B | 4.9x | ||
| Publicly listed | $147M | ($407M) | $3.6B | 16.3x |
Heyuan Biotechnology Public Comps
Heyuan Biotechnology is still privately-owned, but its public comps include Virbac, Neuland Laboratories, Amoytop Biotech, Regencell Bioscience, uniQure, Celldex Therapeutics, Zealand Pharma, Betta Pharmaceuticals, MBX Biosciences and Jilin Aodong.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.7B | $325M | 1.9x | 1.8x | 9.9x | 9.0x | |||
| $201M | $61M | 15.0x | 13.1x | 49.3x | 44.6x | |||
| $551M | $193M | 5.5x | 4.7x | 15.6x | - | |||
| - | ($3M) | - | - | (923.4x) | - | |||
| $16M | ($134M) | 143.6x | 112.7x | (17.3x) | (11.8x) | |||
| $2M | ($255M) | 1520.5x | 1421.3x | (9.2x) | (7.6x) | |||
| $1.4B | $1B | 0.5x | 0.7x | 0.6x | 1.3x | |||
| $538M | $155M | 6.0x | 5.5x | 20.9x | 16.8x | |||
This data is available for Pro users. Sign up to see all Heyuan Biotechnology competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Heyuan Biotechnology
| When was Heyuan Biotechnology founded? | Heyuan Biotechnology was founded in 2013. |
| Where is Heyuan Biotechnology headquartered? | Heyuan Biotechnology is headquartered in Shanghai, China. |
| Is Heyuan Biotechnology publicly listed? | No, Heyuan Biotechnology is a private, VC-backed company. |
| What is Heyuan Biotechnology's valuation? | Heyuan Biotechnology was last valued at $3B in its Series C in June 2020. |
| How much funding has Heyuan Biotechnology raised? | Heyuan Biotechnology has raised $300M across 1 funding round. |
| What was Heyuan Biotechnology's last funding round? | Heyuan Biotechnology's last funding round was a $300M Series C in June 2020, led by Loyal Valley Capital. |
| Who are Heyuan Biotechnology's investors? | Heyuan Biotechnology's investors include Kunlun Capital, Loyal Valley Capital, Jinpu Investment, Sherpa Capital, Morningside and Boyuan Capital. |
| Which companies are comparable to Heyuan Biotechnology? | Companies comparable to Heyuan Biotechnology include ArsenalBio, Formation Bio, Betta Pharmaceuticals, CareDx, Veracyte and GRAIL. |
See companies similar to Heyuan Biotechnology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




